(THE CONVERSATION) The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of ...

Moderna's new flu vaccine application will be reviewed by the FDA after a dispute regarding clinical trial parameters was ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the company's application to market the new kind of influenza vaccine.

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company ...

Viral mimic systems and other tech platforms could enable local testing of vaccine candidates and antiviral therapies. This is important in the context of low-resourced health settings, Africa's focus ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further studies. Federal officials did not immediately comment.

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...